Serum lipocalin-2 is a potential biomarker for the clinical diagnosis of nonalcoholic steatohepatitis

키워드

참고문헌 (46)

1. Shouhed D, "The role of bariatric surgery in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis", Expert Rev Gastroenterol Hepatol, 11, pp.797~811 (2017)
2. Diehl AM, "Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis", N Engl J Med, 377, pp.2063~2072 (2017)
3. Younossi ZM, "Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009", Hepatology, 62, pp.1723~1730 (2015)
4. Zheng KI, "From NAFLD to MAFLD: a “redefining” moment for fatty liver disease", Chin Med J (Engl), 133, pp.2271~2273 (2020)
5. Bedossa P, "Diagnosis of non-alcoholic fatty liver disease", non-alcoholic steatohepatitis: why liver biopsy is essential, 2018, pp.38(Suppl 1), 64~66
6. Sun DQ, "PNPLA3rs738409 is associated with renal glomerular and tubular injury in NAFLD patients with persistently normal ALT levels", Liver Int, 40, pp.107~119 (2020)
7. Wong VW, "Noninvasive biomarkers in NAFLD and NASH - current progress and future promise", Nat Rev Gastroenterol Hepatol, 15, pp.461~478 (2018)
8. Feng G, "Bioinformatics analysis reveals novel core genes associated with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis", Gene, 742, pp.144549~ (2020)
9. Teufel A, "Comparison of gene expression patterns between mouse models of nonalcoholic fatty liver disease and liver tissues from patients", Gastroenterology, 151, pp.513~525.e0 (2016)
10. Zimny S, "Chemokine (CC-motif) receptor-like 2 mRNA is expressed in hepatic stellate cells and is positively associated with characteristics of non-alcoholic steatohepatitis in mice and men", Exp Mol Pathol, 103, pp.1~8 (2017)
11. Friedman SL, "A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis", Hepatology, 67, pp.1754~1767 (2018)
12. Ibrahim SH, "A molecular signature of mouse NASH: a step closer to a human predictive biomarker?", Cell Mol Gastroenterol Hepatol, 5, pp.65~66 (2017)
13. Desterke C, "Lipid related genes altered in NASH connect inflammation in liver pathogenesis progression to HCC: a canonical pathway", Int J Mol Sci, 20, pp.5594~ (2019)
14. Xu G, "Activation of pluripotent genes in hepatic progenitor cells in the transition of nonalcoholic steatohepatitis to pre-malignant lesions", Lab Invest, 97, pp.1201~1217 (2017)
15. Liu XJ, "Characterization of a murine nonalcoholic steatohepatitis model induced by high fat high calorie diet plus fructose and glucose in drinking water", Lab Invest, 98, pp.1184~1199 (2018)
16. "Babraham bioinformatics-FastQC a quality control tool for high throughput sequence data"[URL]
17. Anders S, "Differential expression analysis for sequence count data", Genome Biol, 11, pp.R106~ (2010)
18. Yu G, "clusterProfiler: an R package for comparing biological themes among gene clusters", OMICS, 16, pp.284~287 (2012)
19. Franceschini A, "STRING v9.1: protein-protein interaction networks, with increased coverage and integration", Nucleic Acids Res, 41, pp.D808~D815 (2013)
20. Smoot ME, "Cytoscape 2.8:new features for data integration and network visualization", Bioinformatics, 27, pp.431~432 (2011)
21. Chalasani N, "The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases", Hepatology, 67, pp.328~357 (2018)
22. National Workshop on Fatty Liver and Alcoholic Liver Disease, "Guidelines of prevention and treatment for nonalcoholic fatty liver disease: a 2018 update", Zhonghua Gan Zang Bing Za Zhi, 26, pp.195~203 (2018)
23. Xiao X, "Lipocalin 2: an emerging player in iron homeostasis and inflammation", Annu Rev Nutr, 37, pp.103~130 (2017)
24. Schuster S, "Triggering and resolution of inflammation in NASH", Nat Rev Gastroenterol Hepatol, 15, pp.349~364 (2018)
25. Ye D, "Lipocalin-2 mediates non-alcoholic steatohepatitis by promoting neutrophil-macrophage crosstalk via the induction of CXCR2", J Hepatol, 65, pp.988~997 (2016)
26. Semba T, "The FLS (fatty liver Shionogi) mouse reveals local expressions of lipocalin-2, CXCL1 and CXCL9 in the liver with non-alcoholic steatohepatitis", BMC Gastroenterol, 13, pp.120~ (2013)
27. Takeda K, "Toll-like receptors in innate immunity", Int Immunol, 17, pp.1~14 (2005)
28. Miura K, "Role of gut microbiota and toll-like receptors in nonalcoholic fatty liver disease", World J Gastroenterol, 20, pp.7381~7391 (2014)
29. Arrese M, "Innate immunity and inflammation in NAFLD", NASH, 2016, pp.61, 1294~1303
30. Brenner C, "Decoding cell death signals in liver inflammation", J Hepatol, 59, pp.583~594 (2013)
31. Kazankov K, "The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis", Nat Rev Gastroenterol Hepatol, 16, pp.145~159 (2019)
32. Asimakopoulou A, "Altered mitochondrial and peroxisomal integrity in lipocalin-2-deficient mice with hepatic steatosis", Biochim Biophys Acta Mol Basis Dis, 1863, pp.2093~2110 (2017)
33. van Breda SGJ, "Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction", Toxicology, 393, pp.160~170 (2018)
34. Deis JA, "Adipose Lipocalin 2 overexpression protects against age-related decline in thermogenic function of adipose tissue and metabolic deterioration", Mol Metab, 24, pp.18~29 (2019)
35. Young Chang, "Clinical application of ultrasonography-guided percutaneous liver biopsy and its safety over 18 years", Clinical and Molecular Hepatology, 26(3), pp.318~327 (2020), 대한간학회[DOI]
36. Torres DM, "Diagnosis and therapy of nonalcoholic steatohepatitis", Gastroenterology, 134, pp.1682~1698 (2008)
37. Fung KY, "Performance of serum lipocalin 2 as a diagnostic marker for colorectal cancer", Cancer Biomark, 13, pp.75~79 (2013)
38. Chiang KC, "Lipocalin 2 (LCN2) is a promising target for cholangiocarcinoma treatment and bile LCN2 level is a potential cholangiocarcinoma diagnostic marker", Sci Rep, 6, pp.36138~ (2016)
39. Alwahsh SM, "Lipocalin-2 is a biomarker in rat fatty liver induced by fructose-enriched diet", Z Gastroenterol, 51, pp.P301~ (2013)
40. Asimakopoulou A, "Lipocalin 2(LCN2) expression in hepatic malfunction and therapy", Front Physiol, 7, pp.430~ (2016)
41. Miyake T, "Body mass index is the most useful predictive factor for the onset of nonalcoholic fatty liver disease: a community-based retrospective longitudinal cohort study", J Gastroenterol, 48, pp.413~422 (2013)
42. Min HK, "Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease", Cell Metab, 15, pp.665~674 (2012)
43. Mofrad P, "Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values", Hepatology, 37, pp.1286~1292 (2003)
44. Okamura T, "Creatinine-to-bodyweight ratio is a predictor of incident nonalcoholic fatty liver disease: a population-based longitudinal study", Hepatol Res, 50, pp.57~66 (2020)
45. Lin J, "A low creatinine to body weight ratio predicts the incident nonalcoholic fatty liver disease in nonelderly chinese without obesity and dyslipidemia: a retrospective study", Gastroenterol Res Pract, 2020, pp.4043871~ (2020)
46. Sumida Y, "A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease", J Gastroenterol, 46, pp.257~268 (2011)

관련 논문AI추천